RIPK2 inhibition for the treatment of cancer
Described herein are treatments and patient selection methods for cancers such as prostate cancer, breast cancer, liver cancer, bladder cancer, and melanoma. The treatment involves administering a RIPK2 inhibitor to a subject. The patient selection involves selecting a patient who has increased copy numbers or expression of both RIPK2 and MYC.
1 . A method of treating prostate cancer or inhibiting metastasis of prostate cancer in a subject in need thereof, comprising:
administering a receptor-interacting protein kinase 2 (RIPK2) inhibitor to the subject,
wherein the RIPK2 inhibitor is ponatinib, GSK-583, ODS-101, or a combination thereof, and
wherein if the RIPK2 inhibitor is ponatinib, the cancer is not chronic myeloid leukemia (CML), or Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL).
2 . The method of claim 1 , wherein the RIPK2 inhibitor is ponatinib, and the cancer is not chronic myeloid leukemia (CML), or Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL).
3 . The method of claim 1 , wherein the RIPK2 inhibitor is ponatinib.
4 . A method of claim 1 , wherein the prostate cancer is advanced prostate cancer.
5 . A method of claim 1 , wherein the subject has been determined to have an increased expression of RIPK2 in cancer cells, as compared to non-cancerous cells, OR wherein the subject has been determined to have a RIPK2 copy number gain, a MYC copy number gain, or a RIPK2/MYC copy number co-gain in cancer cells as compared to non-cancerous cells, OR wherein the subject has been determined to have a RIPK2 copy number amplification, a MYC copy number amplification, or a RIPK2/MYC copy number co-amplification in cancer cells as compared to non-cancerous cells.
6 . A method of claim 1 , comprising treating the prostate cancer.
7 . A method of claim 1 , comprising inhibiting prostate cancer metastasis.
8 . A method of claim 1 ,
wherein the subject has been determined to have a RIPK2 copy number gain, a MYC copy number gain, or a RIPK2/MYC copy number co-gain in cancer cells as compared to non-cancerous cells, or
wherein the subject has been determined to have a RIPK2 copy number amplification, a MYC copy number amplification, or a RIPK2/MYC copy number co-amplification in cancer cells as compared to non-cancerous cells.